ISRCTN60358675已完成1 期
An exploratory pharmacoscintigraphic single centre, open-label, crossover study in healthy volunteers to evaluate novel oral modified release semaglutide tablets
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Male
入选标准
- •2. Aged between 18 and 60 years inclusive
- •3. BMI between 18 and 30 kg/m², inclusive. Body weight =50 kg
- •4. Understands and is willing, able, and likely to comply with all study procedures including consumption of meals provided and restrictions
- •5. Demonstrates understanding of the study and willingness to participate as evidenced by voluntary written informed consent (signed and dated) obtained before any trial-related activities
- •6. Good general health with (in the opinion of the Principal Investigator (PI), or medically qualified designee) no clinically significant and/or relevant abnormalities of medical history or prior to dosing evaluations, including physical examination, vital signs, ECG and screening clinical laboratory results
- •7. Unless you have had a vasectomy more than 12 weeks prior to the study starting you must be willing to use a condom with spermicide or practice sexual abstinence with any male partner for the duration of the trial and for 90- days after the last assessment visit. Unless you have had a vasectomy more than 12 weeks prior to study starting you must be willing to abstain from sexual intercourse with women of childbearing potential for the duration of the trial and for 90 days after the last assessment visit OR agree to use a condom in addition to having your female partner use a form of hormonal contraception such as the oral contraceptive pill, implant, hormonal contraceptive injection or an intrauterine device (coil).
排除标准
- •1. Medical history:
- •1.1. Current or recurrent disease/condition that, in the opinion of the PI or medically qualified designee responsible, could affect study conduct; the safety of the subject as a result of participation; and/or the ability of the subject to complete the study or laboratory assessments. For example: hepatic disorders, renal insufficiency, congestive heart failure, conditions known to impact gastric emptying such as migraine or diabetes mellitus and relevant non-self-limiting GI disorders.
- •1.2. A history of acute pancreatitis regardless of aetiology
- •1.3. Family history of pancreatic cancer
- •1.4. Personal or family history of Multiple Endocrine Neoplasia type 2 or medullary thyroid tumour
- •1.5. Current or relevant previous history of serious, severe or unstable psychiatric illness, that may require treatment or make the subject unlikely to fully complete the study, or that presents undue risk from the study medication or procedures
- •1.6. History of previous surgical intervention which could affect GI transit and/or function for example gastric surgery, vagotomy or known adhesions with previous obstructive symptoms
- •1.7. Haematological or biochemical blood test at screening outside normal ranges and deemed clinically significant by the PI or medically qualified designee
- •1.8. Amylase and lipase values from blood tests outside normal ranges
- •1.9. Has a diagnosis of an immunosuppressive disorder or a condition requiring chronic immunosuppression
- •1.10. Any contraindication to the gamma scintigraphy procedure
- •1.11. As a result of a physical examination or screening investigations available prior to dosing evaluations, the PI or medically qualified designee/physician responsible considers the volunteer unfit for the study
- •1.12. Measured body temperature >38°C at screening visit (COVID-19 risk reduction procedure)
- •2. Medications:
- •2.1. Subject is scheduled to take prescribed medication within 14 days prior to the first or any subsequent assessment visit which, in the opinion of the PI or medically qualified designee responsible, will interfere with the study procedures or has the potential to affect gastric emptying and/or gut transit or compromise safety
- •2.2. Subject is scheduled to take over-the-counter (OTC) medication, including vitamins, pro and prebiotics and natural or herbal remedies, within 48 hours prior to the first or any subsequent assessment visit
- •3. Alcohol/substance abuse:
- •3.1. Recent history (within the last year) of alcohol or other substance abuse
- •3.2. Subject has an average weekly alcohol intake of greater than 14 units
- •3.3. Subject has positive urine drugs of abuse test at screening or prior to dosing evaluation
- •3.4. Subject has a positive breath alcohol test at screening or prior to dosing evaluation
- •4. Smoking:
- •4.1. Subject has recently discontinued smoking (less than 3 months).
- •4.2. Subject is currently a smoker or user of nicotine-containing products
- •4.3. Subject has a positive urine cotinine test at screening or prior to dosing evaluation
- •5. Allergy/intolerance:
- •5.1. Subject has a history of allergy to any component of the dosage form or any other allergy, which, in the opinion of the PI or medically qualified designee responsible, contraindicates their participation
- •5.2. Subject has an allergy to any of the contents of the standardised meals
- •5.3. Subject is vegetarian or vegan
- •6. Clinical studies:
- •6.1. Participation in another clinical study (inclusive of final post-study examination) or receipt of an inves
研究者
相似试验
进行中（未招募）
不适用
Single center, therapeutic exploratory clinical trial to evaluate the safety of sodium oxybate (Xyrem) 500 mg/mL oral solution on potential endocrine changes at currently labeled therapeutic dose regimens (4.5 g/day divided into two equal doses)during twelve weeks of treatment of cataplexy in adult patients with narcolepsy. - C00301EUCTR2005-004417-15-BECB Pharma Ltd25
暂停
4 期
A single center and single arm exploratory clinical trial of Honghua Xiaoyao tablets in the treatment of breast hyperplasia (liver stagnation and blood stasis type)breast hyperplasia (liver stagnation and blood stasis type)ITMCTR2024000165Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine
进行中（未招募）
不适用
An open label, single arm, multicenter pharmacokinetic study designed to investigate the serum asparaginase activity associated with the administration of Erwinase dosed intramuscularly in young adult subjects diagnosed with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) with a documented hypersensitivity reaction to native E.coli AsparginaseEUCTR2014-000999-26-PLJazz Pharmaceuticals, Inc.30
进行中（未招募）
不适用
An open label, single arm, multicenter pharmacokinetic study designed to investigate the serum asparaginase activity associated with the administration of Erwinase dosed intramuscularly in young adult subjects diagnosed with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) with a documented hypersensitivity reaction to native E.coli AsparginaseEUCTR2014-000999-26-ESJazz Pharmaceuticals, Inc.30
暂停
1 期
A Clinical Pharmacology Trial of Brexpiprazole Long Acting Injectable (LAI) Administered as a Single Dose in Patients With SchizophreniaSchizophreniaJPRN-jRCT2061210051Matsumaru Takehisa60